Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

0.2300 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

October 14, 2025

Via ACCESS Newswire

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

October 14, 2025

Via ACCESS Newswire

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

October 14, 2025

Via ACCESS Newswire

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

October 09, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 12, 2025

Via Benzinga

Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In ↗

July 02, 2025

The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients.

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 02, 2025

Via Benzinga

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

July 02, 2025

Via ACCESS Newswire

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ ↗

June 11, 2025

CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion.

Via Stocktwits

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

June 11, 2025

Via ACCESS Newswire

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025

Via ACCESS Newswire

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 06, 2025

Via ACCESS Newswire

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug ↗

April 21, 2025

Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market.

Via Stocktwits

The market is filled with gapping stocks in Monday's session. ↗

April 21, 2025

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

What's going on in today's pre-market session ↗

April 21, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

April 21, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 17, 2025

Via Benzinga

BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Secures $2.46M in Registered Direct

April 03, 2025

Via Investor Brand Network

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

April 03, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 03, 2025

Via Benzinga

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

April 02, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 02, 2025

Via Benzinga

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug ↗

April 02, 2025

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 02, 2025

Via Benzinga

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

April 02, 2025

Via ACCESS Newswire

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia ↗

April 02, 2025

U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading.

Via Benzinga

Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket ↗

April 02, 2025

Via Benzinga

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

April 01, 2025

Via ACCESS Newswire

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

March 24, 2025

Via ACCESS Newswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.